For the family in the room when the oncologist runs out of time.

Pancreatic cancer caregiver? Get the research your oncologist doesn't have time for.

14 AI specialist agents analyze your case. Findings + questions to bring to your oncologist, delivered in 48 hours. $99.

Start My Brief — $99

  • 30-50 page personalized briefing
  • 48-hour delivery
  • Refund + free re-brief if not useful

People are paying for the research no one else will compile.

"He was diagnosed at stage 4 the same week we were supposed to fly to my niece's wedding. The oncologist gave us 8 minutes. I came home and read every paper I could find for two weeks straight. I just wanted someone to put it all together — what's standard, what's experimental, what's open right now — so we weren't guessing."

— Maria, caregiver to her husband (pancreatic adenocarcinoma)

"My dad's KRAS-mutant. Folfirinox isn't holding. Every appointment is 'let's keep going for now' and we leave with nothing new. I needed someone to tell me what's actually being studied for his profile — not the brochure stuff."

— James, caregiver to his father

This is for Maria. And James. And every family that has watched a loved one's pancreatic cancer diagnosis arrive in 8 minutes and felt like they were sent home empty-handed.

What you'll get back

Sample findings from a brief like yours. Each rated by how many specialists converged on the evidence.

Emerging

Glutamine Metabolism Targeting in KRAS-Driven Disease

Pancreatic adenocarcinoma is overwhelmingly KRAS-mutant, and KRAS-driven tumors show a metabolic addiction to glutamine. PubMed-indexed studies on glutaminase inhibitors (CB-839 / telaglenastat) and dietary glutamine restriction strategies are in early-phase trials. Evidence is preclinical-to-early-clinical, but the mechanism is well-characterized.

Question to bring to your oncologist: are there open trials testing glutamine-pathway inhibitors that I would qualify for given my KRAS status?

Promising

Gut Microbiome Composition & Immunotherapy Response

The Riquelme et al. work and follow-on research show that gut and intratumoral microbiome composition correlates with long-term survival in pancreatic cancer, and modulates response to immune checkpoint inhibitors. Stool-based microbiome profiling is now clinically available and can inform pre-immunotherapy interventions.

Question to bring to your oncologist: would microbiome profiling be informative before we decide on immunotherapy or clinical trial enrollment?

Promising

Off-Label Repurposed Agents Alongside Standard Care

There is a substantial PubMed-indexed literature on metformin, statins, and antiparasitics (ivermectin, mebendazole) showing anti-cancer signals across multiple solid tumors including pancreatic. Most evidence is observational or preclinical, but several agents are in active phase II trials and have well-established safety profiles when added under physician supervision.

Question to bring to your oncologist: are any repurposed agents reasonable to add alongside the current regimen given comorbidities and current labs?

Sample findings shown are representative of the structure your brief will follow. Yours is tailored to the specific question you submit.

How it works

  1. Tell us your case — One paragraph, in your own words. 60 seconds.
  2. 14 specialists analyze — Independently, in parallel. Each pulls from PubMed, ClinicalTrials.gov, FDA labels.
  3. Convergence ranked — Every finding rated Strong / Moderate / Emerging by how many specialists confirmed it. Disagreement is data.
  4. Briefing delivered — 30-50 pages in your inbox in 48 hours. With references. With questions for your doctor.

Why $99

At a top academic center — Mayo Clinic, MD Anderson, Cleveland Clinic — your case might be reviewed by 5-7 sub-specialists in a tumor board. That access takes weeks of referrals, often travel, and runs $2,000–$5,000 just for the consult.

Insight Swarm convenes 14 specialist agents for your case. Same shape of analysis. 48 hours instead of 6 weeks. $99 instead of $5,000+.

The promise

Read your briefing. If we didn't surface anything you couldn't easily Google, reply to the delivery email within 7 days. Full refund. AND we'll run a second brief on a different question, free. No questions, no upsells.

Medical Advisor at Medical Meditation Corporation: Nikhil Joshi, MD, FRCPC (methodology oversight).

Not medical advice — research summary intended to inform conversations with your medical team.